Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8649166 | 0.88 | EDNRA (0.55) | KMT2AEDNRAMEN1PTGS2ALDH1A1 | |
| SCHEMBL8791812 | 0.80 | EDNRA (0.55) | KMT2AEDNRAMAPK9MAOBPTGS1 | |
| SCHEMBL6315909 | 0.79 | EDNRA (0.57) | EDNRA | |
| SCHEMBL795156 | 0.77 | KMT2A (0.38) | KMT2AEDNRAMEN1ALDH1A1MAPT | |
| SCHEMBL6313692 | 0.77 | EDNRB (0.48) | EDNRA | |
| SCHEMBL7333442 | 0.75 | KMT2A (0.56) | KMT2AEDNRAMEN1ALDH1A1MAPT | |
| SCHEMBL2346146 | 0.73 | KMT2A (0.56) | KMT2AEDNRAMAPK9MEN1PTGS1 | |
| SCHEMBL3694992 | 0.70 | KDM4E (0.43) | KMT2AEDNRAMEN1PTGS1PTGS2 | |
| SCHEMBL11459800 | 0.68 | MAPK9 (0.57) | KMT2AEDNRAMAPK9MEN1PTGS1 | |
| SCHEMBL7333600 | 0.67 | EDNRA (0.47) | KMT2AEDNRAMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-5821256-A | Endothelin receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-10-13 | — | — | US | claimed |
| EP-0758650-A1 | Endothelin receptor antagonists | MERCK PATENT GmbH (DE) | 1997-02-19 | — | — | EP | claimed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-5821256-A | Endothelin receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-10-13 | — | — | US | disclosed |
| EP-0758650-A1 | Endothelin receptor antagonists | MERCK PATENT GmbH (DE) | 1997-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | KMT2A 3059/4885EDNRA 1/4885MAPK9 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.